|
1
|
Ostrom QT, Gittleman H, Liao P, Rouse C,
Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2007–2011. Neuro Oncol.
16(Suppl 4): iv1–iv63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gurney JG and Kadan-Lottick N: Brain and
other central nervous system tumors: Rates, trends and
epidemiology. Curr Opin Oncol. 13:160–166. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fuentes-Raspall R, Vilardell L,
Perez-Bueno F, Joly C, Garcia-Gil M, Garcia-Velasco A and
Marcos-Gragera R: Population-based incidence and survival of
central nervous system (CNS) malignancies in Girona (Spain)
1994–2005. J Neurooncol. 101:117–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tumours register of the health service of
the principality of Asturias for 2013. ISSN: 2176-6885. http://www.hca.es/huca/web/main.asp?id_pagina=29Accessed.
June 25–2015
|
|
5
|
Brem SS, Bierman PJ, Brem H, Butowski N,
Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman
A, Gilbert MR, et al: Central nervous system cancers. J Natl Compr
Canc Netw. 9:352–400. 2011.PubMed/NCBI
|
|
6
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolamide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cohen MH, Shen YL, Keegan P and Pazdur R:
FDA drug approval summary: Bevacizumab (Avastin) as treatment of
recurrent glioblastoma multiforme. Oncologist. 14:1131–1138. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maxwell M, Naber SP, Wolfe HJ,
Hedley-Whyte ET, Galanopoulos T, Neville-Golden J and Antoniades
HN: Expression of angiogenic growt factor genes in primary human
astrocytomas may contribuye to their growt and progression. Cancer
Res. 51:1345–1351. 1991.PubMed/NCBI
|
|
9
|
Takahasi JA, Fukumoto M, Igarashi K, Oda
Y, Kikuchi H and Hatanaka M: Correlation of basic fibroblast growt
factor expresión levels with the degree of malignancy and
vascularity in human gliomas. J Neurosurg. 76:792–798. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combiantion with irinotecan in
recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Norden AD, Young GS, Setayesh K,
Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B,
Drappatz J, et al: Bevacizumab for recurrent malignant gliomas:
Efficacy, toxicity, and patterns of recurrence. Neurology.
70:779–787. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kreisl TN, Kim L, Moore K, Duic P, Royce
C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al:
Phase II trial of single-agent bevacizumab followed by bevacizumab
plus irinotecan at tumor progression in recurrent glioblastoma. J
Clin Oncol. 27:740–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vredenburgh JJ, Desjardins A, Herndon JE
II, Marcello J, Reardon DA, Quinn JA, Quinn JA, Rich JN,
Sathornsumetee S, Gururangan S, et al: Bevacizumab plus irinotecan
in recurrent glioblastoma multiforme. J Clin Oncol. 25:4722–4729.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zuniga RM, Torcuator R, Jain R, Anderson
J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy and
patterns of response and recurrence in patines with recurrent
high-grade gliomas treated with bevacizumab plus irinotecan. J
Neurooncol. 91:329–336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stark-Vance V: Bevacizumab and CPT-11 in
the treatment of relapsed malignant glioma. Neuro Oncol.
7:3692005.(abstr 342).
|
|
16
|
Raval S, Hwang S and Dorsett L:
Bevacizumab and irinotecan in patients with recurrent glioblastoma
multiforme (GBM). J Clin Oncol. 25(Suppl): abstract 2078. 2007.
|
|
17
|
Vredenburgh JJ, Desjardins A, Herndon JE
II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S,
Gururangan S, Wagner M, et al: Phase II trial of bevacizumab and
irinotecan in recurrent malignant glioma. Clin Cancer Res.
13:1253–1259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ali SA, McHayleh WM, Ahmad A, Sehgal R,
Braffet M, Rahman M, Bejjani G and Friedland DM: Bevacizumab and
irinotecan therapy in glioblastoma multiforme: A series of 13
cases. J Neurosurg. 109:268–272. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bokstein F, Shpigel S and Blumenthal DT:
Treatment with bevacizumab and irinotecan for recurrent high-grade
glial tumors. Cancer. 112:2267–2273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cloughesy TF, Prados MD, Wen PY, Mikkelsen
T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I and Friedman HS:
A phase II, randomized, non-comparative clinical trial of the
effect of bevacizumab (BV) alone or in combination with irinotecan
(CPT) on 6-month progression free survival (PFS6) in recurrent,
treatment refractory glioblastoma (GBM). J Clin Oncol. 26(Suppl):
abstract 2010b. 2008.PubMed/NCBI
|
|
21
|
Desjardins A, Reardon DA, Herndon JE II,
Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S,
Sampson J, Bailey L, et al: Bevacizumab plus irinotecan in
recurrent WHO grade 3 malignant gliomas. Clin Cancer Res.
14:7068–7073. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guiu S, Taillibert S, Chinot O,
Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu
B, Catry-Thomas I, et al: Bevacizumab/irinotecan. An active
treatment for recurrent high grade gliomas: Preliminary results of
an ANOCEF multicenter study. Rev Neurol (Paris). 164:588–594.
2008.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gilbert MR, Wang M, Aldape K, Lassman A,
Sorensen AG, Mikkelson T, Groves M, Werner-Wasik M, Regine W and
Mehta M: RTOG 0625: A phase II study of bevacizumab with irinotecan
in recurrent glioblastoma (GBM). J Clin Oncol. 27(Suppl): abstract
2011. 2009.
|
|
24
|
Nghiemphu PL, Liu W, Lee Y, Than T, Graham
C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, et al:
Bevacizumab and chemotherapy for recurrent glioblastoma: A
single-institution experience. Neurology. 72:1217–1222. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Poulsen HS, Grunnet K, Sorensen M, Olsen
P, Hasselbalch B, Nelausen K, Kosteljanetz M and Lassen U:
Bevacizumab plus irinotecan in the treatment patients with
progressive recurrent malignant brain tumours. Acta Oncol.
48:52–58. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cloughesy T, Vredenburgh JJ, Day B, Das A
and Friedman HS: Updated safety and survival of patients with
relapsed glioblastoma treated with bevacizumab in the BRAIN study.
J Clin Oncol. 28(Suppl): abstract 2008. 2010.PubMed/NCBI
|
|
27
|
Ruiz-Sánchez D, Calero MA, Sastre-Heres
AJ, García MT, Hernandez MA, Martinez FM and Peña-Díaz J:
Effectiveness of the bevacizumab-irinotecan regimen in the
treatment of recurrent glioblastomamultiforme: Comparison with
other second-line treatments without this regimen. Oncol Lett.
4:1114–1118. 2012.PubMed/NCBI
|
|
28
|
Henriksson R, Asklund T and Poulsen HS:
Impact of therapy on quality of life, neurocognitive function and
their correlates in glioblastoma multiforme: A review. J
Neurooncol. 104:639–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lamers LM, Stupp R, van den Bent MJ, Al
MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R and
Uyl-de Groot CA: EORTC 26981/22981 NCI-C CE3 Intergroup Study:
Cost-effectiveness of temozolomide for the treatment of newly
diagnosed glioblastoma multiforme. A report from the EORTC
26981/22981 NCI-C CE3 intergroup study. Cancer. 112:1337–1344.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McCabe C, Claxton K and Culyer AJ: The
NICE cost-effectiveness threshold: What it is and what that means.
Pharmacoeconomics. 26:733–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
